|
'''CDPPB''' is a drug used in scientific research which acts as a ] selective for the ] subtype ].<ref name="pmid15537338">{{cite journal |author=Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR |title=Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo |journal=Journal of Medicinal Chemistry |volume=47 |issue=24 |pages=5825–8 |year=2004 |month=November |pmid=15537338 |doi=10.1021/jm049400d |url=}}</ref><ref name="pmid16722652">{{cite journal |author=de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |year=2006 |month=June |pmid=16722652 |doi=10.1021/jm051252j |url=}}</ref><ref name="pmid17303702">{{cite journal |author=Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ |title=Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses |journal=Molecular Pharmacology |volume=71 |issue=5 |pages=1389–98 |year=2007 |month=May |pmid=17303702 |doi=10.1124/mol.106.032425 |url=}}</ref> It has ] effects in animal models,<ref name="pmid15608073">{{cite journal |author=Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL |title=A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=313 |issue=1 |pages=199–206 |year=2005 |month=April |pmid=15608073 |doi=10.1124/jpet.104.079244 |url=}}</ref> and mGluR<sub>5</sub> modulators are under investigation as potential drugs for the treatment of ],<ref name="pmid16719816">{{cite journal |author=Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG |title=Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia |journal=Current Topics in Medicinal Chemistry |volume=6 |issue=8 |pages=771–85 |year=2006 |pmid=16719816 |doi= 10.2174/156802606777057599|url=}}</ref> as well as other applications.<ref name="pmid17511968">{{cite journal |author=Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B |title=Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex |journal=Biological Psychiatry |volume=62 |issue=7 |pages=739–46 |year=2007 |month=October |pmid=17511968 |pmc=2910402 |doi=10.1016/j.biopsych.2006.12.003 |url=}}</ref><ref name="pmid19100966">{{cite journal |author=Gass JT, Olive MF |title=Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory |journal=Biological Psychiatry |volume=65 |issue=8 |pages=717–20 |year=2009 |month=April |pmid=19100966 |pmc=2870714 |doi=10.1016/j.biopsych.2008.11.001 |url=}}</ref> |
|
'''CDPPB''' is a drug used in scientific research which acts as a ] selective for the ] subtype ].<ref name="pmid15537338">{{cite journal |vauthors=Lindsley CW, Wisnoski DD, Leister WH, O'brien JA, Lemaire W, Williams DL, Burno M, Sur C, Kinney GG, Pettibone DJ, Tiller PR, Smith S, Duggan ME, Hartman GD, Conn PJ, Huff JR |title=Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo |journal=Journal of Medicinal Chemistry |volume=47 |issue=24 |pages=5825–8 |date=November 2004 |pmid=15537338 |doi=10.1021/jm049400d }}</ref><ref name="pmid16722652">{{cite journal |vauthors=de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |date=June 2006 |pmid=16722652 |doi=10.1021/jm051252j }}</ref><ref name="pmid17303702">{{cite journal |vauthors=Chen Y, Nong Y, Goudet C, Hemstapat K, de Paulis T, Pin JP, Conn PJ |title=Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses |journal=Molecular Pharmacology |volume=71 |issue=5 |pages=1389–98 |date=May 2007 |pmid=17303702 |doi=10.1124/mol.106.032425 |s2cid=7004830 }}</ref> It has ] effects in animal models,<ref name="pmid15608073">{{cite journal |vauthors=Kinney GG, O'Brien JA, Lemaire W, Burno M, Bickel DJ, Clements MK, Chen TB, Wisnoski DD, Lindsley CW, Tiller PR, Smith S, Jacobson MA, Sur C, Duggan ME, Pettibone DJ, Conn PJ, Williams DL |title=A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=313 |issue=1 |pages=199–206 |date=April 2005 |pmid=15608073 |doi=10.1124/jpet.104.079244 |s2cid=14946765 }}</ref> and mGluR<sub>5</sub> modulators are under investigation as potential drugs for the treatment of ],<ref name="pmid16719816">{{cite journal |vauthors=Lindsley CW, Shipe WD, Wolkenberg SE, Theberge CR, Williams DL, Sur C, Kinney GG |title=Progress towards validating the NMDA receptor hypofunction hypothesis of schizophrenia |journal=Current Topics in Medicinal Chemistry |volume=6 |issue=8 |pages=771–85 |year=2006 |pmid=16719816 |doi= 10.2174/156802606777057599}}</ref> as well as other applications.<ref name="pmid17511968">{{cite journal |vauthors=Lecourtier L, Homayoun H, Tamagnan G, Moghaddam B |title=Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-D-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex |journal=Biological Psychiatry |volume=62 |issue=7 |pages=739–46 |date=October 2007 |pmid=17511968 |pmc=2910402 |doi=10.1016/j.biopsych.2006.12.003 }}</ref><ref name="pmid19100966">{{cite journal |vauthors=Gass JT, Olive MF |title=Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory |journal=Biological Psychiatry |volume=65 |issue=8 |pages=717–20 |date=April 2009 |pmid=19100966 |pmc=2870714 |doi=10.1016/j.biopsych.2008.11.001 }}</ref> |